Japan Lifeline (7575) Q3 2025 earnings summary

Executive summary

• Achieved record-high net sales, operating profit, and net profit for the nine-month period, with double-digit year-over-year growth across key metrics.

• Growth was driven by expanded market penetration of core products, successful competitive positioning, and strategic entry into new market segments, offsetting reimbursement price reductions and higher costs.

• Raised full-year earnings and dividend guidance on the back of strong Q1–Q3 results and a positive Q4 outlook, with the announcement made on January 31, 2025.

Financial highlights

• 9M FYE3/2025 net sales: ¥42,811M (+11.8% YoY); operating profit: ¥9,906M (+17.2% YoY); net profit: ¥7,071M (+14.5% YoY); all at record highs.

• Q3 (Oct–Dec) net sales: ¥14,825M (+12.6% YoY); operating profit: ¥3,646M (+22.5% YoY); net profit: ¥2,635M (+23.2% YoY).

• EPS for 9M: ¥99.37 (+23.1% YoY); Q3 EPS: ¥37.60 (+32.8% YoY).

• Gross margin stable at ~60% (60.5%); operating margin improved to 23.1% for 9M and 24.6% for Q3.

• Comprehensive income increased 17.9% to ¥7,632M.

Outlook and guidance

• Full-year guidance raised: net sales ¥56,800M (+10.5% YoY), operating profit ¥12,600M (+15.7% YoY), net profit ¥9,200M (+22.4% YoY), EPS ¥129.78.

• Dividend per share forecast increased to ¥53.00 (payout ratio ~40%).

• Q4 expected to maintain strong sales momentum, with margins impacted by higher R&D spend.